Apyx Medical Corp Files 8-K, Confirms Nasdaq Listing

TL;DR

**Apyx Medical filed a routine 8-K, no major news, just corporate info.**

AI Summary

Apyx Medical Corp filed an 8-K on January 8, 2024, primarily to update its corporate information and confirm its status as a publicly traded company on the Nasdaq Stock Market, LLC under the ticker APYX. This filing doesn't contain new financial results or major operational changes, but rather serves as a routine disclosure of corporate details. For investors, this means there's no immediate news impacting the stock price, but it confirms the company's continued compliance with SEC reporting requirements.

Why It Matters

This filing is a standard corporate update, confirming Apyx Medical Corp's current registration details and its listing on Nasdaq, which is important for maintaining transparency and investor confidence.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing with no new material financial or operational information, posing minimal risk.

Analyst Insight

This filing is routine and does not provide new information that would warrant immediate investment action. Investors should continue to monitor for future filings that contain financial results or strategic announcements.

Key Numbers

• 001-31885 — Commission File Number (identifies Apyx Medical Corp with the SEC)
• 11-2644611 — I.R.S. Employer Identification No. (identifies Apyx Medical Corp for tax purposes)
• 727-384-2323 — Issuer's telephone number (contact number for Apyx Medical Corp)

Key Players & Entities

• Apyx Medical Corp (company) — the registrant filing the 8-K
• Nasdaq Stock Market, LLC (company) — the exchange where Apyx Medical Corp's Class A common stock is registered
• APYX (company) — the trading symbol for Apyx Medical Corp's Class A common stock
• Delaware (company) — state of incorporation for Apyx Medical Corp
• 5115 Ulmerton Road, Clearwater, Florida 33760 (company) — principal executive offices address for Apyx Medical Corp

FAQ

Filing Documents

• apyx-20240108.htm (8-K) — 25KB
• a2023q4apyxex991revenuerel.htm (EX-99.1) — 18KB
• apyx-20240108_g1.jpg (GRAPHIC) — 21KB
• image2a.jpg (GRAPHIC) — 79KB
• 0000719135-24-000003.txt ( ) — 325KB
• apyx-20240108.xsd (EX-101.SCH) — 2KB
• apyx-20240108_lab.xml (EX-101.LAB) — 24KB
• apyx-20240108_pre.xml (EX-101.PRE) — 12KB
• apyx-20240108_htm.xml (XML) — 3KB

02 - Results of Operations and Financial Condition

Item 2.02 - Results of Operations and Financial Condition On January 8, 2024, Apyx Medical Corporation (the "Company") issued a press release reporting on its preliminary revenue results for the fourth quarter and year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

01 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits (d) Exhibit No. Description 99.1 Press release dated January 8 , 202 4

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 Apyx Medical Corporation By: /s/ Matthew Hill Matthew Hill Chief Financial Officer, Secretary and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR